EXEL vs MDGL
Exelixis, Inc. and Madrigal Pharmaceuticals, Inc., both Healthcare
Exelixis, Inc. is the larger company at $13B against $12B. Over the past year EXEL returned +49% against +7.3% for MDGL. The RyuScore puts EXEL ahead, 80 against 11 out of 100.
| Figure | EXEL | MDGL |
|---|---|---|
| Last close | $59.86 | $472 |
| Market cap | $13B | $12B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 18.8 | n/a |
| 1-year return | +49% | +7.3% |
| 5-year return | +197% | +496% |
| RyuScoresector-relative, 1–10 | 80/100 | 11/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Exelixis, Inc.
Revenue of $629M in Q2 2026, net income $212M. Its largest reported line is Product Gross, 87% of the disclosed total.
Madrigal Pharmaceuticals, Inc.
Revenue of $364M in Q2 2026, net income null.
Open these two in the interactive comparison to add more names, change the period or see the correlation.